Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
60 results about "Frontotemporal dementia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Several disorders that affect the frontal and temporal lobes of the brain.
Derivate von dihydroxyphenylalanin
The invention relates to dihydroxyphenylalanine derivatives, the production thereof, and pharmaceutical compositions containing said dihydroxyphenylalanine derivatives. The invention further relates to the use of said dihydroxyphenylalanine derivatives and pharmaceutical compositions for the treatment and prevention of movement disorders, neurodegenerative diseases, Alzheimer, Parkinson's disease, hemiatrophy hemiparkinsonism, Parkinson's syndrome, Lewy bodies disease, frontotemporal dementia, Lytico-Bodig disease (Parkinsonism-dementia-amyotrophic lateral sclerosis, striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive pallidal atrophy, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X chromosome-linked dystonia (Morbus Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless leg syndrome, Wilson's disease.
Owner:ELLNEUROXX LTD
Use and treatment of di-amino acid repeat-containing proteins associated with als
ActiveUS20160025747A1Reduce stabilityIncrease heightBiocidePeptide/protein ingredientsMedicineAmyotrophic lateral sclerosis
Disclosed herein are methods and compositions for identifying and / or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Anti-trem2 antibodies and methods of use thereof
InactiveUS20190010230A1Nervous disorderImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody fragmentsHumanized antibody
The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and / or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
Owner:ALECTOR LLC
Agents, uses and methods for treatment
ActiveUS20190023788A1Decreased PGRN levelLower Level RequirementsNervous disorderImmunoglobulins against cell receptors/antigens/surface-determinantsAmyotrophic lateral sclerosisNeuro-degenerative disease
The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
Owner:H LUNDBECK AS
Neurodegenerative disorders and muscle diseases implicating pufas
Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and / or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and / or suppress the rate of formation of reactive products and toxic compounds.
Owner:BIOJIVA LLC
Compounds and methods for reducing Tau expression
ActiveUS10407680B2Maintenance and reduction number and volumePreventing or amelioratingOrganic active ingredientsNervous disorderNeuro-degenerative diseaseBiology
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Tau mRNA in a cell or animal, and in certain instances reducing the amount of Tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and / or volume of neurofibrillary inclusions. Such neurodegenerative diseases include tauopathies, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, and Dravet's Syndrome.
Owner:BIOGEN MA INC
New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
InactiveCN101326179AOrganic active ingredientsNervous disorderNeurofibrillary tangleAdditive ingredient
Owner:ASTRAZENECA AB
Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
ActiveUS20160354335A1Improve cognitive functionProtected growthNervous disorderMuscular disorderAlcoholismsHuntingtons chorea
The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and / or neuronal death and / or glucose impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.
Owner:PHARNEXT
Bis-heteroaryl derivatives as modulators of protein aggregation
ActiveUS20190367502A1Improvement in sensorimotorIncrease the number ofOrganic active ingredientsNervous disorderHuntingtons choreaAtrophy
The present invention relates to bis-heteroaryl compounds of formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
Owner:UCB PHARMA SRL
Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
The present invention relates to certain bicyclic bis-heteroaryl compounds of Formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
Owner:UCB PHARMA SRL
Compounds and methods for reducing tau expression
InactiveUS20190211332A1Maintaining and improving motor functionReduce maintenanceNervous disorderDNA/RNA fragmentationBiologyS syndrome
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Tau mRNA in a cell or animal, and in certain instances reducing the amount of Tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and / or volume of neurofibrillary inclusions. Such neurodegenerative diseases include tauopathies, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, and Dravet's Syndrome.
Owner:BIOGEN IDEC MA INC
Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
ActiveUS20190105314A1Improve cognitionImproved motor activityPowder deliveryOrganic active ingredientsHuntingtons choreaMyotonic dystrophy gene
Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.
Owner:ALKAHEST INC
Method of differentially diagnosing different types of dementia
The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.
Owner:KONINKLIJKE PHILIPS ELECTRONICS NV
Therapy for frontotemporal dementia
PendingUS20190328906A1Prevent degradationInhibits and decrease and prevents neuron degeneration and deathNervous disorderPeptidesBrain VentricleMammalian expression
The invention provides methods and uses for delivering progranulin to the central nervous system (CNS) of a mammal. Methods and uses include, for example, administering to a mammal a vector comprising a nucleic acid encoding progranulin, variant, derivative or functional fragment thereof to the mammal's brain ventricle to transduce CNS cells and / or cells that contact the cerebrospinal fluid (CSF) of the mammal such that the cells express the progranulin, variant, derivative or functional fragment thereof.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
Isoquinoline derivatives as perk inhibitors
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Pyrazine compound and preparation method thereof
ActiveCN111793036AOrganic active ingredientsNervous disorderHuntingtons choreaDiabetes Mellitus Complications
The invention relates to a pyrazine compound, a stereoisomer, a tautomer and a pharmaceutically acceptable salt thereof, wherein the pyrazine compound, the stereoisomer, the tautomer and the pharmaceutically acceptable salt thereof can treat Alzheimer's disease, Parkinson's disease, Huntington's disease, frontal temporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis,progressive spinal cord lateral sclerosis, Friedel-Crafts ataxia, neuropathic pain or glaucoma and other neurodegenerative diseases, diabetes mellitus and related diabetic complications, inflammations, oxidative damage and mitochondria-related diseases.
Owner:SHENZHEN OLIVE BIOPHARMACEUTICALS CO LTD
Diagnostic method
ActiveUS20110124010A1Microbiological testing/measurementDisease diagnosisAlpha-synucleinMyelin basic protein
A method of detecting the presence, or monitoring the severity of a condition characterised by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and / or fragments thereof in the macrophages is indicative of the presence of the condition in the patient. The condition and the marker proteins can be: Alzheimer's Disease and the Abeta peptide, Parkinson's Disease and ubiquitin, Multiple Sclerosis and myelin basic protein, FrontoTemporal Dementia and tau, Amyotrophic Lateral Sclerosis and tau, Parkinson's disease, Lewy Body dementia or Alzheimer's Disease and alpha-synuclein.
Owner:INVEN2
Diagnostic method for Alzheimer's disease
ActiveUS9625474B2Reduce phagocytosisAmeliorate amyloid depositionMicrobiological testing/measurementDisease diagnosisAlpha-synucleinMyelin basic protein
A method of detecting the presence, or monitoring the severity of a condition characterized by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and / or fragments thereof in the macrophages is indicative of the presence of the condition in the patient. The condition and the marker proteins can be: Alzheimer's Disease and the Abeta peptide, Parkinson's Disease and ubiquitin, Multiple Sclerosis and myelin basic protein, FrontoTemporal Dementia and tau, Amyotrophic Lateral Sclerosis and tau, Parkinson's disease, Lewy Body dementia or Alzheimer's Disease and alpha-synuclein.
Owner:INVEN2
Neurotrophic peptides for the treatment of tauopathies
ActiveUS9327011B2Same orEffective treatmentTetrapeptide ingredientsPharmaceutical non-active ingredientsMedicineParkinsonism dementia
Peptide 6 and in particular, Peptide 021, may be used to treat tauopathies, such as frontotemporal dementia with Parkinsonism linked to chromosome-17 (FTDP-17) tau, corticobasal degeneration, Pick disease, progressive supranuclear palsy, Guam Parkinsonism dementia complex, dementia pugilistica also known as traumatic encephalopathy or traumatic brain injury, ceroid neuronal lipofusinosis, Hallerworden Sptaz disease, Alzheimer's disease, and adults with Down syndrome.
Owner:RES FOUDATION FOR MENTAL HYGIENE INC
Application of transferrin and transferrin combined sodium oligomannate capsule and composition containing sodium oligomannate capsule
PendingCN112206315ARaise the level of awarenessOrganic active ingredientsNervous disorderLewy bodies dementiaLewy body
The invention provides application of transferrin and transferrin combined sodium oligomannate capsule and composition containing the sodium oligomannate capsule, and in particular relates to application of the transferrin or the transferrin combined sodium oligomannate capsule to preparation of a medicine for preventing or / and improving or / and treating dementia. and the composition containing thesodium oligomannate capsule comprises the sodium oligomannate capsule and the transferrin. The invention has the beneficial effects that the transferrin can improve the cognitive level of a dementiapatient, and with the combined use of the transferrin and the sodium oligomannate capsule, the effect of the sodium oligomannate capsule to prevent, improve and treat Alzheimer's disease and other types of dementia, such as vascular dementia, frontotemporal dementia, lewy body dementia,dementia caused by brain traumas and dementia caused by neuroinflammation, is further improved.
Owner:江苏豪思睦可生物科技有限公司
Misfolded tdp-43 binding molecules
PendingCN111886247ANervous disorderImmunoglobulins against animals/humansAntigenAntigen Binding Fragment
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules,in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and / ortreat a disorder and / or abnormality associated with misfolded TDP-43 including but not limited to frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD, sporadicand familial), and / or Parkinson's disease (PD). The present invention provides modified conformation-specific antigenic peptides and peptide fragments derived from the TDP-43 protein and the antibodies obtainable by said peptides or fragments for use in the diagnosis, prevention, alleviation and / or treatment of TDP-43-related disorders and / or abnormalities.
Owner:AC IMMUNE SA
Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease
PendingCN113811304AOrganic active ingredientsNervous disorderNeuro-degenerative diseasePharmaceutical medicine
The invention concerns a compound of formula 2-phenyl-6-(1H-imidazol-1-yl)quinazoline or a pharmaceutically acceptable salt thereof for use in the treatment of a neurodegenerative disease. The neurodegenerative disease is a disease selected from the group consisting of Alzheimer's disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, prion diseases, HIV-associated dementia and any form of cognitive disorders linked to neurodegeneration, preferably Alzheimer's disease.
Owner:ROTTAPHARM BIOTECH SRL
Neurotrophic peptides for the treatment of tauopathies
ActiveUS20140357572A1Same orEffective treatmentNervous disorderMetabolism disorderMedicineCorticobasal degeneration
Peptide 6 and in particular, Peptide 021, may be used to treat tauopathies, such as frontotemporal dementia with Parkinsonism linked to chromosome-17 (FTDP-17) tau, corticobasal degeneration, Pick disease, progressive supranuclear palsy, Guam Parkinsonism dementia complex, dementia pugilistica also known as traumatic encephalopathy or traumatic brain injury, ceroid neuronal lipofusinosis, Hallerworden Sptaz disease, Alzheimer's disease, and adults with Down syndrome.
Owner:RES FOUDATION FOR MENTAL HYGIENE INC
Pyrazine compounds with multiple effects and preparation method thereof
ActiveCN111808032AGroup 4/14 element organic compoundsSenses disorderHuntingtons choreaDiabetes Mellitus Complications
The invention relates to pyrazine compounds, stereoisomers, tautomers and pharmaceutically acceptable salts of the pyrazine compounds. The pyrazine compounds can be used for treating Alzheimer's disease, Parkinson's disease, Huntington's disease, frontal temporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis, progressive spinal cord lateral sclerosis, Friedel-Crafts ataxia, neuropathic pain or glaucoma and other neurodegenerative diseases, diabetes mellitus and related diabetic complications, inflammation, oxidative damage and mitochondria-related diseases.
Owner:SHENZHEN OLIVE BIOPHARMACEUTICALS CO LTD
Agents, uses and methods for treatment
ActiveUS10894833B2Lower Level RequirementsNervous disorderImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesAmyotrophic lateral sclerosis
The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
Owner:H LUNDBECK AS
Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases
ActiveUS10980780B2Eliminate the effects ofReduce inflammationOrganic active ingredientsNervous disorderNeuro-degenerative diseaseNeuronal disease
The present invention discloses compositions, means and kits thereof for treating neuronal clinical indications in a mammalian subject. The composition comprises, inter alia, a synergistic combination of an anti-inflammatory drug and a DICER activator. The present invention further discloses methods for treating neuronal diseases including Motor neuron diseases (MNDs), ALS, FTD (Frontotemporal Dementia), macular degeneration (AMD) autism, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
Owner:NEUROSENSE THERAPEUTICS LTD
Application of pyrazine compounds with multiple effects in preparation of medicines
The invention relates to pyrazine compounds, stereoisomers, tautomers and pharmaceutically acceptable salts of the pyrazine compounds. The compounds can be used for treating Alzheimer's disease. Parkinson's disease, Huntington's disease, frontal temporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis, progressive spinal cord lateral sclerosis, Friedel-Crafts ataxia, neuropathic pain or glaucoma and other neurodegenerative diseases, diabetes mellitus and related diabetic complications, inflammation, oxidative damage and mitochondria-related diseases.
Owner:SHENZHEN OLIVE BIOPHARMACEUTICALS CO LTD
Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
PendingUS20200054622A1Symptoms improvedOrganic active ingredientsDispersion deliveryHuntingtons choreaDepressant
Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.
Owner:ALKAHEST INC
Application of ramulus et folium picrasmae extract to preparing medicines or healthcare products for preventing and treating neurodegenerative diseases
InactiveCN109793765AOrganic active ingredientsNervous disorderDementia with Lewy bodiesHuntingtons chorea
The invention discloses application of ramulus et folium picrasmae extract to preparing medicines or healthcare products for preventing and treating neurodegenerative diseases. The ramulus et folium picrasmae extract comprises ramulus et folium picrasmae ethyl acetate extract and / or beta-carboline alkaloid separated from ramulus et folium picrasmae. The neurodegenerative diseases include Alzheimer's diseases, Parkinson's diseases, dementia with Lewy bodies, frontotemporal dementia, Huntington's diseases and amyotrophic lateral sclerosis. The application has the advantage that novel treatment pathways further can be provided to preventing and / or treating the neurodegenerative diseases.
Owner:CHINA PHARM UNIV
Methods of treating neurodegenerative diseases using indane acetic acid derivatives which penetrate the blood brain barrier
InactiveUS20180200230A1Organic active ingredientsNervous disorderHuntingtons choreaDementia with Lewy bodies
This invention describes the use of indane acetic acid derivatives which are dual PPAR delta / gamma agonists, and which penetrate the Blood Brain Barrier and achieve effective brain to plasma drug levels at non-toxic doses, for the treatment of neurodegenerative diseases including one or more of the following: Alzheimer's Disease (AD); Huntington's Disease (HD); Parkinson's Disease (PD); Amyotrophic Lateral Sclerosis (ALS); Frontal Temporal Dementia (FTD); Corticobasal Degeneration (CBD); Progressive Supranuclear Palsey (PSP); Dementia with Lewy Bodies (DLB); or Multiple Sclerosis (MS).
Owner:DARA BIOSCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com